202 related articles for article (PubMed ID: 32607519)
1. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Klein S; Pekosz A; Park HS; Ursin R; Shapiro J; Benner S; Littlefield K; Kumar S; Naik HM; Betenbaugh M; Shrestha R; Wu A; Hughes R; Burgess I; Caturegli P; Laeyendecker O; Quinn T; Sullivan D; Shoham S; Redd A; Bloch E; Casadevall A; Tobian A
medRxiv; 2020 Jun; ():. PubMed ID: 32607519
[TBL] [Abstract][Full Text] [Related]
2. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population.
Klein SL; Pekosz A; Park HS; Ursin RL; Shapiro JR; Benner SE; Littlefield K; Kumar S; Naik HM; Betenbaugh MJ; Shrestha R; Wu AA; Hughes RM; Burgess I; Caturegli P; Laeyendecker O; Quinn TC; Sullivan D; Shoham S; Redd AD; Bloch EM; Casadevall A; Tobian AA
J Clin Invest; 2020 Nov; 130(11):6141-6150. PubMed ID: 32764200
[TBL] [Abstract][Full Text] [Related]
3. SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors.
Benner SE; Patel EU; Laeyendecker O; Pekosz A; Littlefield K; Eby Y; Fernandez RE; Miller J; Kirby CS; Keruly M; Klock E; Baker OR; Schmidt HA; Shrestha R; Burgess I; Bonny TS; Clarke W; Caturegli P; Sullivan D; Shoham S; Quinn TC; Bloch EM; Casadevall A; Tobian AAR; Redd AD
J Infect Dis; 2020 Nov; 222(12):1974-1984. PubMed ID: 32910175
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2
Salazar E; Kuchipudi SV; Christensen PA; Eagar TN; Yi X; Zhao P; Jin Z; Long SW; Olsen RJ; Chen J; Castillo B; Leveque C; Towers DM; Lavinder J; Gollihar JD; Cardona J; Ippolito GC; Nissly RH; Bird IM; Greenawalt D; Rossi RM; Gontu A; Srinivasan S; Poojary IB; Cattadori IM; Hudson PJ; Joselyn N; Prugar L; Huie K; Herbert A; Bernard DW; Dye J; Kapur V; Musser JM
bioRxiv; 2020 Jun; ():. PubMed ID: 32577662
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.
Li L; Tong X; Chen H; He R; Lv Q; Yang R; Zhao L; Wang J; Xu H; Liu C; Chen G; Chen S; Li C; Qiao J; Yang J; Wu Y; Liu Z
Transfusion; 2020 Aug; 60(8):1765-1772. PubMed ID: 32627216
[TBL] [Abstract][Full Text] [Related]
6. Donors for SARS-CoV-2 Convalescent Plasma for a Controlled Clinical Trial: Donor Characteristics, Content and Time Course of SARS-CoV-2 Neutralizing Antibodies.
Körper S; Jahrsdörfer B; Corman VM; Pilch J; Wuchter P; Blasczyk R; Müller R; Tonn T; Bakchoul T; Schäfer R; Juhl D; Schwarz T; Gödecke N; Burkhardt T; Schmidt M; Appl T; Eichler H; Klüter H; Drosten C; Seifried E; Schrezenmeier H
Transfus Med Hemother; 2021 May; 48(3):137-147. PubMed ID: 34177417
[TBL] [Abstract][Full Text] [Related]
7. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
Larsen SE; Berube BJ; Pecor T; Cross E; Brown BP; Williams B; Johnson E; Qu P; Carter L; Wrenn S; Kepl E; Sydeman C; King NP; Baldwin SL; Coler RN
bioRxiv; 2021 Jul; ():. PubMed ID: 34230930
[TBL] [Abstract][Full Text] [Related]
8. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
Yuan Y; Yu L; Jin Z; Wang Y; Gao M; Ding H; Zhuo X; Zhu X; Gao F; Zheng X; Ying G; Xu X; Kong Q; Lu S; Lv H
Front Cell Infect Microbiol; 2021; 11():650487. PubMed ID: 33796489
[TBL] [Abstract][Full Text] [Related]
9. Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan.
Li C; Yu D; Wu X; Liang H; Zhou Z; Xie Y; Li T; Wu J; Lu F; Feng L; Mao M; Lin L; Guo H; Yue S; Wang F; Peng Y; Hu Y; Wang Z; Yu J; Zhang Y; Lu J; Ning H; Yang H; Fu D; He Y; Zhou D; Du T; Duan K; Dong D; Deng K; Zou X; Zhang Y; Zhou R; Gao Y; Zhang X; Yang X
Nat Commun; 2021 Jul; 12(1):4144. PubMed ID: 34230476
[TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients; Subanalyses of a Phase 2 Clinical Study.
Terpos E; Politou M; Sergentanis TN; Mentis A; Rosati M; Stellas D; Bear J; Hu X; Felber BK; Pappa V; Pagoni M; Grouzi E; Labropoulou S; Charitaki I; Ntanasis-Stathopoulos I; Moschandreou D; Bouhla A; Saridakis S; Korompoki E; Giatra C; Bagratuni T; Pefanis A; Papageorgiou S; Spyridonidis A; Antoniadou A; Kotanidou A; Syrigos K; Stamoulis K; Panayiotakopoulos G; Tsiodras S; Alexopoulos L; Dimopoulos MA; Pavlakis GN
Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33260775
[TBL] [Abstract][Full Text] [Related]
11. Qualification of ELISA and neutralization methodologies to measure SARS-CoV-2 humoral immunity using human clinical samples.
Larsen SE; Berube BJ; Pecor T; Cross E; Brown BP; Williams BD; Johnson E; Qu P; Carter L; Wrenn S; Kepl E; Sydeman C; King NP; Baldwin SL; Coler RN
J Immunol Methods; 2021 Dec; 499():113160. PubMed ID: 34599915
[TBL] [Abstract][Full Text] [Related]
12. Utilization of the Abbott SARS-CoV-2 IgG II Quant Assay To Identify High-Titer Anti-SARS-CoV-2 Neutralizing Plasma against Wild-Type and Variant SARS-CoV-2 Viruses.
Lin YJ; Evans DH; Robbins NF; Orjuela G; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Tuite A; Yi QL; O'Brien SF; Drews SJ
Microbiol Spectr; 2022 Oct; 10(5):e0281122. PubMed ID: 36125288
[TBL] [Abstract][Full Text] [Related]
13. Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays.
Valdivia A; Torres I; Latorre V; Francés-Gómez C; Albert E; Gozalbo-Rovira R; Alcaraz MJ; Buesa J; Rodríguez-Díaz J; Geller R; Navarro D
Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):485-494. PubMed ID: 33404891
[TBL] [Abstract][Full Text] [Related]
14. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.
Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925
[TBL] [Abstract][Full Text] [Related]
15. Clinical validation of the Siemens quantitative SARS-CoV-2 spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers.
Irsara C; Egger AE; Prokop W; Nairz M; Loacker L; Sahanic S; Pizzini A; Sonnweber T; Holzer B; Mayer W; Schennach H; Loeffler-Ragg J; Bellmann-Weiler R; Hartmann B; Tancevski I; Weiss G; Binder CJ; Anliker M; Griesmacher A; Hoermann G
Clin Chem Lab Med; 2021 Jul; 59(8):1453-1462. PubMed ID: 33837679
[TBL] [Abstract][Full Text] [Related]
16. Response kinetics of different classes of antibodies to SARS-CoV2 infection in the Japanese population: The IgA and IgG titers increased earlier than the IgM titers.
Kurano M; Morita Y; Nakano Y; Yokoyama R; Shimura T; Qian C; Xia F; He F; Zheng L; Ohmiya H; Kishi Y; Okada J; Yoshikawa N; Nakajima K; Nagura Y; Okazaki H; Jubishi D; Moriya K; Seto Y; Yasui F; Kohara M; Wakui M; Kawamura T; Kodama T; Yatomi Y
Int Immunopharmacol; 2022 Feb; 103():108491. PubMed ID: 34954559
[TBL] [Abstract][Full Text] [Related]
17. High-Throughput Neutralization and Serology Assays Reveal Correlated but Highly Variable Humoral Immune Responses in a Large Population of Individuals Infected with SARS-CoV-2 in the US between March and August 2020.
Zhang S; Ma P; Orzechowski M; Lemmer A; Rzasa K; Bagnall J; Barkho S; Chen M; He L; Neitupski R; Tran V; Ackerman R; Gath E; Bond A; Frongillo G; Cleland T; Golas A; Gaca A; Fitzgerald M; Kelly K; Hazegh K; Dumont L; Hoffman C; Homer M; Marks P; Woolley A; Wong S; Gomez J; Livny J; Hung D
mBio; 2023 Apr; 14(2):e0352322. PubMed ID: 36786604
[TBL] [Abstract][Full Text] [Related]
18. Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.
Jazbec K; Jež M; Žiberna K; Mali P; Ramšak Ž; Potokar UR; Kvrzić Z; Černilec M; Gracar M; Šprohar M; Jovanovič P; Vuletić S; Rožman P
Virol J; 2023 Mar; 20(1):53. PubMed ID: 36973781
[TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial.
Madariaga MLL; Guthmiller JJ; Schrantz S; Jansen MO; Christensen C; Kumar M; Prochaska M; Wool G; Durkin-Celauro A; Oh WH; Trockman L; Vigneswaran J; Keskey R; Shaw DG; Dugan H; Zheng NY; Cobb M; Utset H; Wang J; Stovicek O; Bethel C; Matushek S; Giurcanu M; Beavis KG; di Sabato D; Meltzer D; Ferguson MK; Kress JP; Shanmugarajah K; Matthews JB; Fung JF; Wilson PC; Alverdy JC; Donington JS
J Intern Med; 2021 Apr; 289(4):559-573. PubMed ID: 33034095
[TBL] [Abstract][Full Text] [Related]
20. Antibody response to SARS-CoV-2 for more than one year - kinetics and persistence of detection are predominantly determined by avidity progression and test design.
Scheiblauer H; Nübling CM; Wolf T; Khodamoradi Y; Bellinghausen C; Sonntagbauer M; Esser-Nobis K; Filomena A; Mahler V; Maier TJ; Stephan C
J Clin Virol; 2022 Jan; 146():105052. PubMed ID: 34920374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
